Among the clinical studies of third-generation EGFR TKIs in the first-line setting, 6 patients with ILD were recorded as osimertinib-related in the global FLAURA study while grade 3 ILD occurred in one patient as severe TRAE in the FLAURA China study [21–23]. The gene discussed is EGFR; the disease is interstitial lung disease.